Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GEHC
GEHC logo

GEHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
63.490
Open
62.515
VWAP
62.99
Vol
8.36M
Mkt Cap
28.87B
Low
62.000
Amount
526.39M
EV/EBITDA(TTM)
10.68
Total Shares
454.89M
EV
37.02B
EV/OCF(TTM)
18.27
P/S(TTM)
1.38
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
Show More

Events Timeline

(ET)
2026-04-29
16:40:00
Major U.S. Averages Close Slightly Lower, Nasdaq Edges Up
select

News

Newsfilter
8.5
13:40 PMNewsfilter
PinnedGE HealthCare Unveils Next-Gen MR Technologies at ISMRM 2026
  • Technology Showcase: At ISMRM 2026, GE HealthCare unveiled its next-generation helium-free 1.5T MR and advanced 3T scanners, integrating deep learning technologies aimed at accelerating research processes and enhancing clinical application efficiency, thereby driving innovation in the medical imaging field.
  • AI-Driven Workflow: The SIGNA One workflow ecosystem simplifies MRI processes and improves imaging consistency, which is expected to enhance the efficiency of researchers and technologists, ultimately improving patient experiences and reinforcing reproducibility in clinical research.
  • Deep Learning Acceleration: GE HealthCare's Sonic DL technology is projected to benefit 85% of MR exams through deep learning acceleration, enhancing image quality and signal-to-noise ratio, further advancing clinical applications in cardiology and oncology.
  • Sustainability Commitment: The newly launched SIGNA Sprint helium-free technology reduces helium usage to below 1% while maintaining clinical efficiency, reflecting GE HealthCare's strategic goal of promoting high-impact MR operations alongside a commitment to sustainability.
Fool
9.5
05-02Fool
Inflationary Pressures Squeeze GE Healthcare's Profit Margins
  • Profit Warning: Following the release of its Q1 2026 earnings, GE Healthcare's stock fell 11.3% in a week, primarily due to inflationary pressures eroding profit margins, with management forecasting a $0.15 decline in EPS, highlighting the cost challenges faced by the company.
  • Rising Costs: Management outlined a $250 million increase in costs, with $100 million attributed to memory chips, $100 million to oil and freight costs, and $50 million to raw materials like tungsten, significantly impacting profitability.
  • Sales Cycle Impact: The long sales cycles of GE Healthcare's high-ticket imaging and visualization equipment hinder the company's ability to quickly raise prices to offset rising costs, and while it sells shorter-cycle products, they are insufficient to alleviate the cost pressures.
  • Stable Revenue Outlook: Despite the cost pressures, GE Healthcare maintains its full-year organic revenue growth guidance of 3%-4%, indicating that revenue growth prospects remain intact, with expectations for improved revenue and margin outlook in late 2026 and into 2027, making the stock appealing to long-term investors.
NASDAQ.COM
2.0
05-02NASDAQ.COM
GE Healthcare Stock Drops 11.3% Due to Rising Costs
  • Earnings Guidance Cut: Following the Q1 2026 earnings report, GE Healthcare lowered its EPS guidance from $4.95-$5.15 to $4.80-$5.00 due to $250 million in rising costs, directly impacting profitability and investor sentiment.
  • Sales Cycle Impact: The company's long sales cycles for high-ticket imaging equipment delay the effect of price increases on revenue, and while it offers shorter-cycle products, this agility is insufficient to counteract rising costs effectively.
  • Cost Composition Analysis: Management highlighted that rising costs stem from memory chips, oil, and raw materials, contributing $100 million each from chips and oil, and $50 million from materials, leading to a projected EPS reduction of $0.43 in 2026, despite plans to mitigate costs.
  • Stable Revenue Growth Outlook: GE Healthcare maintains its full-year organic revenue growth guidance of 3%-4%, indicating no issues with revenue growth prospects, and expects gradual improvement in revenue and margins as long-cycle sales convert into revenue over time.
NASDAQ.COM
5.0
05-01NASDAQ.COM
GE HealthCare and Anika Executives Increase Stock Holdings
  • CFO Purchase at GE HealthCare: GE HealthCare's CFO James Saccaro bought 3,310 shares at $60.60 each on Friday, totaling $200,585, indicating confidence in the company's future despite a slight 0.1% drop in stock price that day.
  • CEO Investment in Anika Therapeutics: Anika Therapeutics' CEO Stephen D. Griffin purchased 12,200 shares at $12.29 each for a total of $149,881 on Thursday, reflecting optimism about the company's prospects, coinciding with a 17.4% increase in stock price that day.
  • Investment Performance: Griffin's investment is currently up 22.3%, based on a trading high of $15.02, showcasing the success of his buying decision and potentially boosting market confidence in Anika.
  • Market Reaction Analysis: While GE HealthCare's stock experienced a slight decline, executive purchases are generally viewed as positive signals for future company performance, which may influence investor confidence and stock price trends in the long term.
Globenewswire
7.0
04-30Globenewswire
GE HealthCare Faces Investor Claims Investigation
  • Poor Financial Performance: GE HealthCare reported diluted earnings per share of $0.85 for Q1 2026, a significant drop from $1.23 in the same period last year, indicating a substantial decline in profitability that may erode investor confidence.
  • Revised Earnings Guidance: The company lowered its full-year 2026 adjusted earnings per share guidance to a range of $4.80 to $5.00, down from the previous range of $4.95 to $5.15, reflecting a pessimistic outlook on future profitability that could impact shareholder investment decisions.
  • Increased Cost Pressures: GE HealthCare anticipates input costs to rise by approximately $250 million in 2026 due to inflation, and while the company plans to offset some of these pressures through pricing and cost control measures, the short-term effectiveness remains uncertain.
  • Sharp Stock Price Decline: Following the earnings report, GE HealthCare's stock price plummeted, damaging investor interests and prompting Johnson Fistel to investigate whether the company complied with federal securities laws, potentially leading to more investors seeking legal recourse.
NASDAQ.COM
4.5
04-29NASDAQ.COM
Mixed Close for US Stocks as Oil Prices Surge
  • Oil Price Surge Impacts Market: WTI crude oil prices surged over 6% on Wednesday to a three-week high due to the US maintaining its naval blockade of Iran, raising inflation expectations and negatively impacting the stock market.
  • Fed Policy Influence: The Federal Reserve kept the federal funds rate unchanged at 3.50% to 3.75% during its latest meeting, despite dissent from four members against easing bias, reflecting concerns over economic uncertainty that may dampen investor confidence.
  • Strong Tech Stock Performance: The Nasdaq 100 index rose 0.58%, driven by strong earnings from NXP Semiconductors and Seagate Technology, with shares up 25% and over 10% respectively, indicating robust demand for AI infrastructure.
  • Housing Data Exceeds Expectations: US March housing starts unexpectedly rose 10.8% to 1.502 million, significantly surpassing the expected decline to 1.380 million, demonstrating resilience in the housing market that could provide support for stocks.
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
Wall Street analysts forecast GEHC stock price to rise
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
80.00
Averages
92.25
High
105.00
Current: 0.000
sliders
Low
80.00
Averages
92.25
High
105.00
Evercore ISI
Outperform
to
Outperform
downgrade
$85 -> $80
AI Analysis
2026-04-30
Reason
Evercore ISI
Price Target
$85 -> $80
AI Analysis
2026-04-30
downgrade
Outperform
to
Outperform
Reason
Evercore ISI lowered the firm's price target on GE HealthCare to $80 from $85 and keeps an Outperform rating on the shares.
JPMorgan
Robbie Marcus
Neutral
downgrade
$80 -> $65
2026-04-30
Reason
JPMorgan
Robbie Marcus
Price Target
$80 -> $65
2026-04-30
downgrade
Neutral
Reason
JPMorgan analyst Robbie Marcus lowered the firm's price target on GE HealthCare to $65 from $80 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GEHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for GE Healthcare Technologies Inc (GEHC.O) is 12.45, compared to its 5-year average forward P/E of 18.07. For a more detailed relative valuation and DCF analysis to assess GE Healthcare Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.07
Current PE
12.45
Overvalued PE
19.98
Undervalued PE
16.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.40
Current EV/EBITDA
11.60
Overvalued EV/EBITDA
12.94
Undervalued EV/EBITDA
9.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.72
Current PS
1.23
Overvalued PS
1.98
Undervalued PS
1.46

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what should i buy
Intellectia · 41 candidates
Market Cap: >= 10.00BRegion: USMarket Cap Category: mega, largeNet Margin: >= 10.00Beta: ModerateRiskPe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
MSFT logo
MSFT
Microsoft Corp
3.10T
GS logo
GS
Goldman Sachs Group Inc
277.81B
AXP logo
AXP
American Express Co
226.22B
BBVA logo
BBVA
Banco Bilbao Vizcaya Argentaria SA
131.73B
AEM logo
AEM
Agnico Eagle Mines Ltd
108.41B
BMO logo
BMO
Bank of Montreal
108.32B
Show US
Intellectia · 35 candidates
Market Cap: >= 10.00BRegion: USBeta: ModerateRiskPe Ttm: 5 - 30Return On Equity: >= 10.0%Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
MSFT logo
MSFT
Microsoft Corp
3.10T
HD logo
HD
Home Depot Inc
349.60B
GS logo
GS
Goldman Sachs Group Inc
277.81B
AXP logo
AXP
American Express Co
226.22B
ADBE logo
ADBE
Adobe Inc
100.50B
PNC logo
PNC
PNC Financial Services Group Inc
91.28B
je veux trader sur le nasdaq 100
Intellectia · 16 candidates
Price: $10.00 - $500.00Analyst Consensus: Strong Buy, Moderate BuyBeta: ModerateRiskIs Index Component: NDX
Ticker
Name
Market Cap$
top bottom
AAPL logo
AAPL
Apple Inc
3.76T
GOOG logo
GOOG
Alphabet Inc
3.70T
MSFT logo
MSFT
Microsoft Corp
2.98T
NFLX logo
NFLX
Netflix Inc
324.56B
ISRG logo
ISRG
Intuitive Surgical Inc
172.54B
PDD logo
PDD
PDD Holdings Inc
142.36B
NASDAQ100 stock with fairly or undervalue
Intellectia · 10 candidates
Analyst Consensus: Strong Buy, Moderate Buy, HoldPe Ttm: 8 - 22P/B Ratio: <= 4.00Is Index Component: NDXEv Ebitda: <= 15
Ticker
Name
Market Cap$
top bottom
FANG logo
FANG
Diamondback Energy Inc
44.13B
PDD logo
PDD
PDD Holdings Inc
152.56B
PYPL logo
PYPL
PayPal Holdings Inc
53.15B
BIIB logo
BIIB
Biogen Inc
25.32B
TMUS logo
TMUS
T-Mobile US Inc
211.11B
CTSH logo
CTSH
Cognizant Technology Solutions Corp
41.28B
how do i create a customized screener
Intellectia · 94 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midNet Margin: >= 5.00Beta: ModerateRiskPe Ttm: 10 - 30Return On Equity: >= 10.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
PDD logo
PDD
PDD Holdings Inc
150.37B
BBVA logo
BBVA
Banco Bilbao Vizcaya Argentaria SA
141.76B
AEM logo
AEM
Agnico Eagle Mines Ltd
103.10B
BMO logo
BMO
Bank of Montreal
96.25B
PNC logo
PNC
PNC Financial Services Group Inc
91.17B
USB logo
USB
US Bancorp
86.26B
show me stocks that have beta =0.8 Alfa =+5
Intellectia · 25 candidates
Market Cap: 20.00B - 50.00BBeta: ModerateRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
DHI logo
DHI
D.R. Horton Inc
45.93B
DAL logo
DAL
Delta Air Lines Inc
45.02B
KGC logo
KGC
Kinross Gold Corp
43.05B
EL logo
EL
Estee Lauder Companies Inc
42.48B
JD logo
JD
JD.com Inc
41.25B
TCOM logo
TCOM
Trip.com Group Ltd
40.50B

Whales Holding GEHC

M
Menora Mivtachim Provident Funds
Holding
GEHC
+11.70%
3M Return
C
Castle Hook Partners LP
Holding
GEHC
+10.77%
3M Return
S
Stonegate Investment Group, LLC
Holding
GEHC
+8.80%
3M Return
N
NewEdge Advisors, LLC
Holding
GEHC
+8.73%
3M Return
O
Omega Advisors, Inc.
Holding
GEHC
+7.04%
3M Return
S
Salem Investment Counselors, Inc.
Holding
GEHC
+6.41%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is GE Healthcare Technologies Inc (GEHC) stock price today?

The current price of GEHC is 63.47 USD — it has increased 3.47

What is GE Healthcare Technologies Inc (GEHC)'s business?

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

What is the price predicton of GEHC Stock?

Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is GE Healthcare Technologies Inc (GEHC)'s revenue for the last quarter?

GE Healthcare Technologies Inc revenue for the last quarter amounts to 5.13B USD, increased 7.41

What is GE Healthcare Technologies Inc (GEHC)'s earnings per share (EPS) for the last quarter?

GE Healthcare Technologies Inc. EPS for the last quarter amounts to 0.85 USD, decreased -30.89

How many employees does GE Healthcare Technologies Inc (GEHC). have?

GE Healthcare Technologies Inc (GEHC) has 54000 emplpoyees as of May 11 2026.

What is GE Healthcare Technologies Inc (GEHC) market cap?

Today GEHC has the market capitalization of 28.87B USD.